← All trials
NCT01760967
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2013
- Primary completion
- Jan 1, 2016
- Completion date
- Jan 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 203
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Wakayama Medical UniversityLead sponsor
- Tohoku UniversityStudy chair
- Hirosaki UniversityStudy director
- Hyogo Medical UniversityStudy director
- Osaka City UniversityCollaborator
- Sapporo Medical UniversityCollaborator
- Tohoku UniversityCollaborator
- Osaka City General HospitalCollaborator
- National Hospital Organization Kyoto Medical CenterCollaborator
- Saga UniversityCollaborator
- Yamaguchi Grand Medical CenterCollaborator
- Hirosaki UniversityCollaborator
- Tohoku UniversityReponsible party - principal investigator
- Hyogo Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.